Sequencing-Based Fetal Testing Market Heats up as Verinata Plans 2012 Launch for Down Syndrome Dx
May 04, 2011
Sequencing-Based Fetal Testing Market Heats up as Verinata Plans 2012 Launch for Down Syndrome Dx
The timing of Verinata's commercial test coincides with the planned launches of trisomy 21 tests by Sequenom and LifeCodexx, both of which plan to commercialize their sequencing-based tests at the end of the year or early next year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- LifeCodexx Begins Clinical Validation Study of Sequencing-Based T21 Test
June 29, 2011 / Clinical Sequencing News - Lo Team Finds Targeted, SNP-Based Approach for T21 Detection 'Less Robust' than Shotgun Sequencing
May 30, 2012 / Clinical Sequencing News - Quake Group Issued Patent for Detection of Fetal Aneuploidy with Next-Gen Sequencing
August 31, 2011 / Clinical Sequencing News - Sequenom Outlicenses Technology for T21 Test, Returns Rights of Separate Patent to TrovaGene
August 17, 2011 / Clinical Sequencing News - Verinata Secures $46.5M for Development, Commercialization of Fetal Trisomy Test
August 9, 2011 / Clinical Sequencing News